Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.

Circulation research - 13 Sept 2013

Moreno Jonathan D, Yang Pei-Chi, Bankston John R, Grandi Eleonora, Bers Donald M, Kass Robert S, Clancy Colleen E

Abstract excerpt

RATIONALE: The antianginal ranolazine blocks the human ether-a-go-go-related gene-based current IKr at therapeutic concentrations and causes QT interval prolongation. Thus, ranolazine is contraindicated for patients with preexisting long-QT and those with repolarization abnormalities. However, with its preferential targeting of late INa (INaL), patients with disease resulting from increased INaL from inherited...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Action Potentials
Share to Anti-Arrhythmia Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computer Simulation

Share to Ether-A-Go-Go Potassium Channels

Share to Long QT Syndrome

Share to Piperazines

Share to Sodium Channel Blockers

Share to Sodium Channels

Source

Open in PubMed Open full text

Identifiers

PMID: 23897695
DOI: 10.1161/CIRCRESAHA.113.301971
PMCID: PMC3896218

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.PMID 23897695Read ↗

The efficacy of Ranolazine on E1784K is altered by temperature and calcium.Semantic proximity Read ↗

Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.Semantic proximity Read ↗

Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?Semantic proximity Read ↗

Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.Semantic proximity Read ↗

Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.Semantic proximity Read ↗

In silico assessment of Y1795C and Y1795H SCN5A mutations: implication for inherited arrhythmogenic syndromes.Semantic proximity Read ↗

Late cardiac sodium current can be assessed using automated patch-clampSemantic proximity Read ↗

Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome.Semantic proximity Read ↗

In silico risk assessment for drug-induction of cardiac arrhythmia.Semantic proximity Read ↗

Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine.Semantic proximity Read ↗

The role of late I Na in development of cardiac arrhythmias.Semantic proximity Read ↗

The impact of uncertainty in hERG binding mechanism on <i>in silico</i> predictions of drug-induced proarrhythmic riskSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.